Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Inhibitex
company
About
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1994
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$20M
Inhibitex has raised a total of
$20M
in funding over 2 rounds. Their latest funding was raised on
Feb 11, 2002 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 11, 2002 | Series Unknown | $20M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Inhibitex is funded by 1 investors.
CDP Sofinov
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
